Stock Comparison

PFE vs SRPT

Pfizer Inc vs Sarepta Therapeutics Inc

The Verdict

SRPT takes this one.

PFE

Pfizer Inc

4.0

out of 10

Proceed with Caution

Winner

SRPT

Sarepta Therapeutics Inc

6.8

out of 10

Solid Pick

Head-to-Head

$146.4B

Market Cap

$1.9B

19.5

P/E Ratio

29.0

11.8%

Profit Margin

3.0%

8.4%

Return on Equity

4.9%

0.7

Debt-to-Equity

0.7

Moderate

Overall Risk

Moderate

4.0

DVR Score

6.8

The Deep Dive

PFE4.0/10

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...

Full PFE Analysis

SRPT6.8/10

Score Change Explanation: The previous analysis (2026-04-05) highlighted "persistent commercial execution issues for Elevidys, reflected in Q4 2025's wider-than-expected loss and reduced 2026 revenue guidance." The Q1 2026 earnings, reported on May 6, 2026, represent a material positive change. Sarepta reported a significant swing to GAAP operating income of $358.4 million and GAAP net income of $...

Full SRPT Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.